GeneDx Corp (WGS) - Price to Earnings Multiple

Corporate emblem and logo of Sema4 (WGS)

GeneDx Holdings Corp. dominates the diagnosis of rare pathologies thanks to the largest exome database and AI analytics. The mass adoption of whole-genome sequencing in pediatrics is accelerating the path to profitability. The P/E ratio visualizes market expectations, where the -13.80 metric captures the current valuation level. The modernization of robotic lines and high laboratory utilization will ensure further growth in market capitalization.

genedx.com - WGS Price to Earnings Ratio (period 04/28/2023 - 11/17/2026)

Analytical breakdowns for GeneDx Holdings Corp.

- market price and analyst price targets:
Comprehensive company analysis:GeneDx
Flagship merchandise of GeneDx

GeneDx Holdings Corp. (WGS) is achieving operational profitability through high-precision pediatric genetics, for which demand remains independent of macroeconomic conditions. The price-to-earnings ratio measures the cost of one dollar of current earnings, allowing for an assessment of the balance between fundamental reliability and growth potential. By analyzing the current market P/E of GeneDx Holdings Corp. (WGS), an investor determines the extent of the premium paid for the business's future expansion rates.

Key competitors

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Market Cap to Net Income Ratio Ultragenyx (RARE)|BEAM: P/E Multiple|Sarepta Therapeutics, Inc. (SRPT) - P/E Multiple|TWST (twistbioscience.com) - P/E Multiple|10x Genomics, Inc. (TXG) - Business Payback Period|Price to Earnings Ratio NTLA (Intellia Therapeutics, Inc.)|STOK - Market Cap to Earnings|Price to Earnings Ratio biolifesolutions.com BLFS|Business Payback Period Wave Life Sciences Corp (WVE)|MAZE - Price to Earnings Ratio|Company Value to Net Income SION (Sionna Therapeutics Inc)|PRME: P/E Multiple|Taysha - Company Value to Net Income|Price to Earnings Ratio uniQure NV|Price to Earnings Multiple MGTX (MeiraGTx PLC)|Price to Earnings Ratio RGNX (regenxbio.com)|Solid Biosciences Inc. - Price to Earnings Multiple|Price to Earnings Ratio Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Market Cap to Earnings|BNTC - Price to Earnings Ratio|Design Pharma - Market Price to Net Income Ratio|RCKT (Rocket Pharmaceuticals Inc) - Price to Earnings Ratio|4D Molecular Therapeutics (FDMT) - P/E Multiple|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio